D
Sell
3/28/2025Upgraded
Coeptis Therapeutics Holdings, Inc. (COEP) was upgraded to D- from E+ on 3/28/2025 due to a noticeable increase in the total return index and volatility index.
E
Sell
1/6/2025Upgraded
Coeptis Therapeutics Holdings, Inc. (COEP) was upgraded to E+ from E on 1/6/2025 due to an increase in the volatility index and total return index.
E
Sell
12/20/2024Downgrade
Coeptis Therapeutics Holdings, Inc. (COEP) was downgraded to E from E+ on 12/20/2024 due to a decline in the volatility index and valuation index.
E
Sell
9/10/2024Upgraded
Coeptis Therapeutics Holdings, Inc. (COEP) was upgraded to E+ from E on 9/10/2024 due to an increase in the volatility index.
E
Sell
8/23/2024Downgrade
Coeptis Therapeutics Holdings, Inc. (COEP) was downgraded to E from E+ on 8/23/2024 due to a substantial decline in the solvency index, growth index and volatility index.
E
Sell
8/22/2024Upgraded
Coeptis Therapeutics Holdings, Inc. (COEP) was upgraded to E+ from E on 8/22/2024 due to an increase in the volatility index.
E
Sell
8/7/2024Downgrade
Coeptis Therapeutics Holdings, Inc. (COEP) was downgraded to E from E+ on 8/7/2024 due to a large decline in the solvency index, total return index and volatility index. Debt to equity increased from 0.27 to 0.54, and the quick ratio declined from 0.5 to 0.26.
E
Sell
2/21/2024Upgraded
Coeptis Therapeutics Holdings, Inc. (COEP) was upgraded to E+ from E on 2/21/2024 due to an increase in the valuation index, volatility index and total return index.
E
Sell
2/5/2024Downgrade
Coeptis Therapeutics Holdings, Inc. (COEP) was downgraded to E from E+ on 2/5/2024 due to a decline in the volatility index, growth index and total return index. EBIT declined 117.27% from -$3.6M to -$7.81M, earnings per share declined from -$0.1427 to -$0.2349, and operating cash flow declined 2.92% from -$1.9M to -$1.96M.
E
Sell
12/9/2022Downgrade
Coeptis Therapeutics Holdings, Inc. (COEP) was downgraded to E+ from D- on 12/9/2022 due to a decline in the total return index and volatility index.
D
Sell
11/15/2022Upgraded
Coeptis Therapeutics Holdings, Inc. (COEP) was upgraded to D- from E+ on 11/15/2022 due to a large increase in the solvency index, growth index and valuation index. The quick ratio increased from 0.56 to 1.71, debt to equity declined from 1.86 to 0.56, and earnings per share increased from -$0.2536 to -$0.1414.
E
Sell
11/10/2022Downgrade
Coeptis Therapeutics Holdings, Inc. (COEP) was downgraded to E+ from D- on 11/10/2022 due to a noticeable decline in the total return index and volatility index.
